Vor to Participate in Two Upcoming Investor Conferences
Vor Biopharma (Nasdaq: VOR) announced participation in two virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Biopharma (Nasdaq: VOR) announced participation in two virtual investor conferences. The first is the H.C. Wainwright BioConnect 2022, with a pre-recorded presentation available on January 10, 2022, starting at 7:00 AM ET. The second event is the 2022 B Riley Virtual Oncology Conference, featuring a live webcast fireside chat on January 27, 2022, at 10:30 AM ET. Both presentations will be accessible through the company’s website, along with archived replays.
Vor Biopharma focuses on engineering hematopoietic stem cells to improve blood cancer treatments.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was -0.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences:
H.C. Wainwright BioConnect 2022 Virtual Conference
Presentation Date: Monday, January 10, 2022
Time: Pre-recorded on-demand presentation available beginning at 7:00 AM ET
2022 B Riley Virtual Oncology Conference
Fireside Chat Live Webcast Date: Thursday, January 27, 2022
Time: 10:30 AM ET
The live and on demand webcasts of both presentations will be available on the Company's website at www.vobrbio.com. An archived replay of each webcast will also be available.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
chris.brinzey@westwicke.com
Media:
Sarah Spencer
Vice President, Corporate Communications, Vor
+1 857-242-6076
sspencer@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.